United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the alzheimer's type (ad). rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with parkinson’s disease (pd). rivastigmine tartrate capsules are contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)] - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)] isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary    there are no adequate data on the developmental risks associated with the use of rivastigmine tartrate in pregnant women. in animals, no adverse effects on embryo-fetal development were observed at oral doses 2 to 4 t

United States - English - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the alzheimer's type (ad). rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with parkinson’s disease (pd). rivastigmine tartrate capsules are contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)] -  a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)] isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)]. risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine tartrate in pregnant women. in animals, no adverse effects on embryo-fetal development were observed at oral doses 2 to 4 time

United States - English - NLM (National Library of Medicine)

american health packaging - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the alzheimer's type (ad). rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with parkinson's disease (pd). rivastigmine tartrate capsules are contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description ( 11)]. - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions ( 5.2)]. isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions ( 6.2)]. risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine tartrate in pregnant women. in animals, no adverse effects on embryo-fetal development were obse

United States - English - NLM (National Library of Medicine)

ajanta pharma limited - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia of the alzheimer's type. rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia associated with parkinson’s disease. rivastigmine tartrate is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)]. - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . pregnancy category b there are no adequate and well-controlled studies in pregnant women. reproduction studies conducted in pregnant rats and rabbits at oral doses up to 2.3 mg-base/kg/day, or 2 (rat) and 4 (rabbit) times the maximum recommended

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - rivastigmine - hard capsule - rivastigmine 1.5 mg - psychoanaleptics

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - rivastigmine - hard capsule - rivastigmine 3 mg - psychoanaleptics

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - rivastigmine - hard capsule - rivastigmine 4.5 mg - psychoanaleptics

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - rivastigmine - hard capsule - rivastigmine 6 mg - psychoanaleptics

Canada - English - Health Canada

dr reddy's laboratories ltd - rivastigmine (rivastigmine hydrogen tartrate) - capsule - 1.5mg - rivastigmine (rivastigmine hydrogen tartrate) 1.5mg - parasympathomemetic (cholinergic) agents

Canada - English - Health Canada

dr reddy's laboratories ltd - rivastigmine (rivastigmine hydrogen tartrate) - capsule - 3.0mg - rivastigmine (rivastigmine hydrogen tartrate) 3.0mg - parasympathomemetic (cholinergic) agents